{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02302599",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CHIN-PLAGH-ST-003"
      },
      "Organization": {
        "OrgFullName": "Chinese PLA General Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells to Treat Type 2 Diabetes",
      "OfficialTitle": "Efficacy and Safety of Umbilical-cord Mesenchymal Stem Cells in Chinese Adults With Type 2 Diabetes: a Single Center, Double-blind, Randomized, Placebo-controlled Trial",
      "Acronym": "UC-MSCs"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2021",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 2013",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "November 12, 2014",
      "StudyFirstSubmitQCDate": "November 26, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 27, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 1, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 3, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yiming Mu",
        "ResponsiblePartyInvestigatorTitle": "Director",
        "ResponsiblePartyInvestigatorAffiliation": "Chinese PLA General Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Chinese PLA General Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Umbilical cord mesenchymal stem cells indicate the therapeutic effects and safety on type 2 diabetes by characteristics of secretion and immune Immunomodulation.",
      "DetailedDescription": "Umbilical cord mesenchymal stem cells can improve insulin resistance of the target tissues, reduce the islet progressive damage, ease or regenerate of the islet beta cells and improve hyperglycemic state of diabetes by secreting a variety of cytokines. It can induce damaged alpha cells differentiate into beta cells in the islet transformation to realize the islet beta cells in situ regeneration by improving microenvironment of islet beta cells. Umbilical cord mesenchymal stem cells also have immunosuppressive effect, it can promote islet cell repair and regeneration by the inhibition of T cell mediated immune response to beta cells."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Type 2 Diabetes",
          "Mesenchymal Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "UC-MSCs (1.5×106/kg) or the same volume of placebo (suspension liquid without UC-MSCs)",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignMaskingDescription": "All investigators and participants were masked to treatment allocation. The independent data monitoring committee and the statisticians supporting the committee's activities were the only people with access to unblinded data.",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "103",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Umbilical cord mesenchymal stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Umbilical cord mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Controlled suspension liquid",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients receive Controlled suspension liquid",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Controlled suspension liquid"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Umbilical cord mesenchymal stem cells",
            "InterventionDescription": "Infusion treatment",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Umbilical cord mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Controlled suspension liquid",
            "InterventionDescription": "Infusion treatment",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Controlled suspension liquid"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D",
            "PrimaryOutcomeDescription": "proportion of patients with HbA1c <7.0% and daily insulin reduction ≥50% from baseline to 48 weeks",
            "PrimaryOutcomeTimeFrame": "48 weeks from baseline"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D",
            "SecondaryOutcomeDescription": "Changes of insulin requirement, HbA1c and proportion of patients reaching the HbA1c target (<7.0%)",
            "SecondaryOutcomeTimeFrame": "48 weeks from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D",
            "SecondaryOutcomeDescription": "Change of islet β cell function and insulin resistance",
            "SecondaryOutcomeTimeFrame": "48 weeks from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D",
            "SecondaryOutcomeDescription": "Fever, pruritus, nausea and vomiting, anaphylactic shock, phlebitis，tumor formation, infection, impaired liver and kidney function.",
            "SecondaryOutcomeTimeFrame": "48 weeks from baseline"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\n20 ≤ age ≤ 65 years;\nDuration of type 2 diabetes ≤20 years;\n24.0 kg/m2 ≤ BMI ≤40.0 kg/m2;\nStable exogenous insulin dose between 0.5-1.0 U/Kg/Day with or without oral hypoglycemic agents (Dipeptidyl peptidase-4 (DPP-4) inhibitor, Glucagon like peptide 1 receptor (GLP-1R) agonist and Sodium-glucose co-transporter 2 (SGLT-2) inhibitor excluded) for at least 3 months;\n7.0% ≤ HbA1c ≤ 12.0%;\nFasting C-peptide ≥ 1ng/ml;\nWillingness to participate in the trial.\n\nExclusion Criteria:\n\nPatients with ketonuria, tumor, serum creatinine level more than 175μmol/L, myocardial infarction in the previous year, current angina or heart failure, more than one major vascular event, retinopathy requiring laser treatment, malignant hypertension, uncorrected endocrine disorder, occupations precluding insulin therapy;\nSevere concurrent illness limiting life expectancy, inadequate understanding of the study protocol, drug abuse, pregnant willing and allergic constitution.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "weidong HAN",
            "OverallOfficialAffiliation": "Chinese PLA General Hospital",
            "OverallOfficialRole": "Study Director"
          },
          {
            "OverallOfficialName": "yiming MU",
            "OverallOfficialAffiliation": "Chinese PLA General Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Chinese PLA General Hospital",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100039",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23770360",
            "ReferenceType": "background",
            "ReferenceCitation": "Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q, Tong C, Ti D, Dong L, Cheng Y, Mu Y, Liu J, Fu X, Han W. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun. 2013 Jul 5;436(3):418-23. doi: 10.1016/j.bbrc.2013.05.117. Epub 2013 Jun 11."
          },
          {
            "ReferencePMID": "16681924",
            "ReferenceType": "background",
            "ReferenceCitation": "Wang XL, Lu JM, Pan CY, Mu YM, Dou JT, Ba JM. [Characteristics of the daily blood glucose profiles of impaired glucose tolerance and type 2 diabetes mellitus subjects by continuous glucose monitoring system]. Zhonghua Yi Xue Za Zhi. 2006 Mar 14;86(10):674-7. Chinese."
          },
          {
            "ReferencePMID": "22618776",
            "ReferenceType": "background",
            "ReferenceCitation": "Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, Shen J, Cheng Y, Fu X, Han W. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes. 2012 Jun;61(6):1616-25. doi: 10.2337/db11-1141."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Chinese PLA General Hospital Endocrinology medical characteristics",
            "SeeAlsoLinkURL": "http://www.301hospital.com.cn"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003920",
            "ConditionMeshTerm": "Diabetes Mellitus"
          },
          {
            "ConditionMeshId": "D000003924",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 2"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafAsFound": "Diabetes",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6271",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 2",
            "ConditionBrowseLeafAsFound": "Type 2 Diabetes",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}